Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response
Abstract Acquired or innate lack of response to standard HER2-targeted therapies remains a clinical issue in patients with HER2-positive breast…
Abstract Acquired or innate lack of response to standard HER2-targeted therapies remains a clinical issue in patients with HER2-positive breast…